

Dietary Intake, Fatty Acid Profile in Plasma and Neutrophil Phospholipids, and Serum Antioxidant Levels in Patients with Crohn's Disease

Yuko Kawakami¹⁾ and Hiroyuki Okada²⁾

¹⁾Department of Human Nutrition, Chugokugakuen University, Okayama 701-0197, Japan

²⁾Department of Medicine and Medical Science, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan

To elucidate the efficacy of dietary therapy for Crohn's disease, we analyzed dietary intake, fatty acid composition of phospholipids in plasma and neutrophils, serum fat-soluble vitamin levels, and oxygen radical absorbance capacity in twenty Crohn's disease patients (15 males and 5 females, 11 with ileitis and 9 with ileocolitis, 30.6 ± 8.2 year), who were treated at the Department of Gastroenterology of Okayama University Hospital. Total fat intake, fat energy ratio and linoleic acid intake were significantly lower, while protein and carbohydrate intakes were significantly higher, in the patients than in age and sex-matched controls. In the neutrophil phospholipids of Crohn's disease patients, significantly higher levels of total n-6 polyunsaturated fatty acid and lower levels of docosahexaenoic acid were observed. The concentrations of serum retinol and β -carotene but not α -tocopherol were significantly lower and serum oxygen radical absorbance capacity was also lower than in the controls. Significant correlations between serum oxygen radical absorbance capacity and zinc ($r=0.797$, $p<0.001$) concentrations were observed in the Crohn's disease patients. A diet restricting the intake of n-6 polyunsaturated fatty acid and antioxidative trace minerals and vitamins may be recommended for the nutritional management of Crohn's disease patients.

Key Words: Crohn's disease, diet, fatty acid, trace mineral, fat-soluble vitamin, neutrophil fatty acid

Introduction

Nutrition may play an important role in the pathogenesis and treatment of inflammatory bowel diseases (IBD) [1, 2, 3]. Several studies suggest an association between dietary factors and the onset of Crohn's disease (CD), [3] however, few have examined the relationship between dietary intake and relapse of

CD. A low intake of dietary fiber [4] or high intake of meat, or protein [5] may be implicated in the relapse of CD. Although the pathogenesis of inflammatory bowel diseases is not fully understood, many suspect that diet and various dietary factors may play a modulating role in the disease process [6].

Various epidemiological, experimental and clinical data suggest that the immune response may be sensitive to changes in dietary fatty acid composition [7] because long chain polyunsaturated fatty acids (PUFA) are the precursors of eicosanoids, which participate in the regulation of immunological and inflammatory responses. The balance between oxidant and antioxidant systems is suggested to be

¹⁾Corresponding author.

Yuko kawakami

Department of Human Nutrition, Faculty of Contemporary Life Science,
Chugokugakuen University, 83 Niwase Okayama 701-0197, Japan
Tel & Fax: +81 86 293 1074

important in the pathogenesis and maintenance of tissue injury in CD. Reduced plasma antioxidant concentrations and increased oxidative DNA damage in patients with Crohn's disease and Ulcerative Colitis (UC) were reported [8].

Adequate nutritional management of CD as a moderator of intestinal inflammation may be required for remission of the disease. In this study, therefore, to elucidate the efficacy of dietary therapy for CD, we analyzed the qualitative and quantitative dietary intake, fatty acid composition of phospholipids in plasma and neutrophils, serum levels of fat-soluble vitamins, retinol, β -carotene and α -tocopherol, and Oxygen Radical Absorbance Capacity (ORAC), and evaluated the effects of nutritional factors on the clinical parameters.

Methods

Subjects

Twenty CD patients were examined in the present study. They were all outpatients treated at the Department of Gastroenterology of Okayama University Hospital. Of the patients, 11 had ileitis and 9 had ileocolitis. The diagnosis of CD was based on accepted clinical, radiographic, endoscopic, and histologic criteria [9]. All patients were in remission. Nineteen patients were medicated with 5-aminosalicylic acid (5-ASA), 2 with azathioprin and 15 with an elemental diet at the time of the study. Five patients consumed regular diets. Control subjects were age and sex-matched healthy volunteers, 12 males and 5 females (29.4 ± 13.1 year).

This experiment was performed in accordance with the principles of the Declaration of Helsinki of the World Medical Association, and informed consent was obtained from all the subjects. This study was approved by our institutional review board.

Estimation of dietary intake

Dietary intake was assessed using a food-frequency questionnaire. Energy, major nutrients and fatty acid consumption were calculated using a method reported by Suzuki et al [10].

Fatty acid analysis

Fasted blood was drawn into tubes containing disodium EDTA. Plasma was separated after the centrifugation of blood samples at $1,600 \times g$ for 15 min at 4°C and stored at -80°C until assayed. To

obtain neutrophils, a 3.5-ml sample of undiluted blood was layered onto 3ml of Mono Poly Resolving Medium (Dainippon Pharmaceuticals, Osaka, Japan) and centrifuged at $400 \times g$ for 20 min at 4°C . The neutrophil layer was drawn off into another tube. The neutrophils were washed 3 times with ice-cold saline, and stored at -80°C prior to use.

Total lipid was extracted from plasma and neutrophils suspended in 0.5ml of saline according to the method of Bligh and Dyer [11]. Total phospholipid was separated by one-dimensional thin-layer chromatography using silica gel plates (Silica Gel 60, Merck, Darmstadt, Germany) and a solvent system of petroleum ether/ethyl ether/acetic acid (80: 20: 1, v/v/v). The spots corresponding to phospholipid were scraped from the plates and transmethylated for 2h at 85°C with 2ml of acetyl-chloride methanol (5: 50, v/v). The fatty acid composition of total phospholipid was analyzed according to a method described previously [12].

Analysis of fat-soluble vitamins in plasma

Retinol, α -tocopherol and carotenoids were extracted from plasma and analyzed using the method reported by Milne et al. [13]. Briefly, 1ml of methanol was added to each sample (0.2ml of plasma plus 0.8ml of distilled water) and extracted twice with 3ml of dichloromethane and 6ml of n-hexane. After shaking and centrifugation (3,000rpm, 10°C , 15min), the upper layer was collected and evaporated under reduced pressure. The residue was dissolved in $50 \mu\text{l}$ of acetonitrile-dichloromethane-methanol (70: 20: 10, v/v/v), and a $50\text{-}\mu\text{l}$ aliquot was injected into the HPLC system. The system was composed of a reverse-phase column (YMC s-5 120A ODS, $6 \times 150\text{mm}$, Yamamura Chemical Co., Kyoto, Japan) and integrator (CR-4A, Shimadzu Co., Kyoto, Japan). The injected sample was eluted isocratically with acetonitrile-dichloromethane-methanol (70: 20: 10, v/v/v), at a flow rate of 1ml/min, with detectors set at 290nm, 350nm and 450nm. Retinol, α -tocopherol, and β -carotene were quantified by determining the peak areas calibrated against known amounts of standards.

Oxygen radical absorbance capacity (ORAC) assay

Serum total antioxidant capacity was measured using the manual version of the oxygen radical absorbance capacity (ORAC) assay as described by Cao et

al. [14]. One run of the ORAC assay comprised one blank, one standard and 6 serum samples. Phosphate buffer (1.75ml) and R-phycoerythrin (R-PE, 3.73mg/l; 100 μ l, Sigma, St Louis, MO, US) were added to each of 8 fluorimeter cuvettes. The cuvettes were preincubated for 15min at 37°C. A volume of 100 μ l of buffer (blank), 20 μ M Trolox (standard, Aldrich Chemical Co., Milwaukee, WI) or diluted serum (sample) was then added. The reaction was started by the addition of 320mM 2,2-azobis (2-amidino-propane) dihydrochloride (AAPH, Wako Pure Chemicals Co., Ltd., Osaka, Japan) solution. The fluorescence was measured using the JASCO FP-6300 fluorescence spectrophotometer (emission wavelength 575nm, excitation 495nm). The cuvettes were incubated at 37°C during measurements and the fluorescence was recorded every 2min it had diminished to less than 5% of the initial value. The final result was determined by calculating the difference of area under the R-PE decay curve between the blank and a sample, and expressed using Trolox equivalents.

TNF- α assay

Evaluation of serum TNF- α was performed using commercially available enzyme-amplified sensitive immunoassays (IMMUNOTECH, Marseille, France). The minimal detectable concentration of TNF- α was 5pg/ml.

Statistical analysis

All statistical calculations were performed using SPSS software. Results are expressed as means \pm standard deviations. The significance of differences was determined with an unpaired two-tailed t-test and a Mann-Whitney U-test. Correlation coefficients were calculated by Spearman's rank-correlation analysis when appropriate. Two-sided p values less than 0.05 were considered significant.

Result

The body mass index (BMI) and the findings of clinical parameters in the controls and the patients with CD are shown in Table 1. The BMI was within the normal range for 19 patients. The BMI of 1 patient was low (14.1). Although white blood cell (WBC) counts were also within the normal range, the lymphocyte ratio and lymphocytes were significantly lower in the patients than the controls. Serum total protein, albumin and hemoglobin concentrations

were also significantly lower in the CD patients. The serum sialic acid level was significantly higher than in the controls. There were no significant differences in serum, TNF- α (21.7 ± 14.9 , 20.2 ± 10.6 pg/ml), and zinc (76.1 ± 15.6 , 82.5 ± 14.6 mg/dl) levels between the CD patients and controls. The serum copper (126.0 ± 25.5 , 90.2 ± 26.1 mg/dl, respectively) levels were significantly higher ($P < 0.001$) than in the controls.

Table 2 shows intakes of energy and major nutrients. In the CD patients, fat intake and the fat energy ratio were significantly lower, while protein and carbohydrate intakes were significantly higher.

Table 1 BMI and clinical parameters in controls and patients with Crohn's disease

	Gender	Controls (M=12, F=5)	Patients (M=15, F=5)
Age		29.4 \pm 13.1	30.6 \pm 8.2
BMI (kg/m ²)		21.4 \pm 2.5	20.5 \pm 2.7
Hemoglobin (g/dl)	M	15.6 \pm 0.9	13.0 \pm 1.5*
	F	13.5 \pm 0.7	11.4 \pm 2.2*
WBC (/ μ l)		5,053 \pm 621	5,910 \pm 1676
Lymphocyte ratio (%)		42.3 \pm 2.6	22.7 \pm 11.8***
Lymphocytes (/ μ l)		2,167 \pm 640	1,237 \pm 543***
Total protein (g/dl)		7.7 \pm 0.4	7.3 \pm 0.7*
Albumin (g/dl)		4.8 \pm 0.3	4.0 \pm 0.5*
Sialic acid (mg/dl)		0.2 \pm 0.1	1.3 \pm 2.0*

Data are the mean \pm standard deviation. ***p<0.001, *p<0.05; compared with controls.

BMI: body mass index

Table 2 Energy and nutrient intakes in controls and patients with Crohn's disease

(/day)	Controls (n=17)	Patients (n=20)
Energy (kcal/kg IBW)	31 \pm 9	35 \pm 5
Fat (g/kg IBW)	1.1 \pm 0.3	0.4 \pm 0.3***
Fat energy ratio (%)	29.7 \pm 7.8	11.6 \pm 7.4***
Protein (g/kg IBW)	1.1 \pm 0.3	1.4 \pm 0.3***
Carbohydrate (g/kg IBW)	4.1 \pm 1.0	6.4 \pm 1.4***
Retinoid (μ g/day)	1,216 \pm 2,017	1,424 \pm 380
Vitamin C (mg/day)	85 \pm 58	141 \pm 80
Vitamin E (mg/day)	9.0 \pm 3.5	14.8 \pm 4.7***
Zinc (mg/day)	8.0 \pm 2.7	10.0 \pm 2.6*
Copper (mg/day)	1.0 \pm 0.3	1.3 \pm 0.2**
Soluble dietary fiber (g/day)	3.1 \pm 1.1	2.1 \pm 1.4**
Insoluble dietary fiber (g/day)	8.8 \pm 3.2	6.8 \pm 4.8**

Data are the mean \pm standard deviation. ***p<0.001, **p<0.01, *p<0.05; compared with controls

IBW: ideal body weight

In the patients, vitamin E, zinc and copper intakes were significantly higher than the controls. Ingested amounts of dietary fatty acids are summarized in Table 3. In the patients, significantly lower intakes of monounsaturated fatty acid and n-6 polyunsaturated fatty acid (PUFA), especially linoleic acid, were observed compared with the controls. Among n-3 PUFAs, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) levels were significantly higher in the CD patients than the controls. Therefore, the n-6/n-3 PUFA ratio was significantly lower in the CD patients.

Fatty acid profiles of plasma and neutrophils in the controls and the CD patients are shown in Table 4.

Table 3 Dietary fatty acid intakes in controls and patients with Crohn's disease

Fatty acid (g/day)	Controls (n=17)	Patients (n=20)
Saturated fatty acid	17.65 ± 10.36	6.52 ± 5.35***
Monounsaturated fatty acid	21.12 ± 10.81	7.77 ± 6.16**
Polyunsaturated fatty acid	13.18 ± 5.33	7.20 ± 3.65***
Total n-6 PUFA	9.39 ± 3.40	5.60 ± 3.00***
Linoleic acid (18: 2n-6)	10.55 ± 4.31	5.47 ± 2.95***
Arachidonic acid (20: 4n-6)	0.11 ± 0.05	0.13 ± 0.06
Total n-3 PUFA	2.46 ± 1.18	1.96 ± 1.14***
α -Linolenic acid (18: 3n-3)	1.76 ± 0.78	0.79 ± 0.51***
EPA (20: 5n-3)	0.19 ± 0.18	0.35 ± 0.24***
DHA (22: 6n-3)	0.38 ± 0.30	0.60 ± 0.41***
n-6/n-3 PUFA ratio	4.7 ± 1.3	3.0 ± 1.4***

Data are the mean ± standard deviation. ***p<0.001, **p<0.01; compared with controls.

PUFA; polyunsaturated fatty acid, EPA; eicosapentaenoic acid, DHA; docosahexaenoic acid

In the plasma and neutrophil phospholipids, an abnormal fatty acid profile was observed in the CD patients. In the plasma phospholipids, significantly low levels of n-6 PUFA, especially linoleic acid was recognized in CD patients compared with control subjects. In the neutrophil phospholipids, saturated fatty acid was significantly lower, and total PUFA, n-6 PUFA, arachidonic acid and DHA were higher in the CD Patients than the control subjects. Additionally, in the plasma and neutrophil phospholipids, the arachidonic acid/ linoleic acid ratio in CD patients was significantly higher than those of control subjects. There was no significant correlation among the fatty acid composition in neutrophils and TNF- α , CRP or sialic acid levels.

Serum retinol and β -carotene concentrations were significantly lower in the CD patients than the controls (Table 5). The serum ORAC value was also

Table 5 Serum fat-soluble vitamin concentrations and ORAC values in controls and patients with Crohn's disease

	Controls (M=12, F=5)	Patients (M=15, F=5)
Retinol (μ mol/L)	2.51 ± 2.17	0.28 ± 0.22*
β -Carotene (μ mol/L)	1.16 ± 2.04	0.14 ± 0.03*
α -Tocopherol (μ mol/L)	23.6 ± 14.9	23.3 ± 12.6
Zinc (μ g/dL)	82.5 ± 14.6	76.1 ± 15.6
Copper (μ g/dL)	90.2 ± 26.1	126.0 ± 25.5***
ORAC value (μ mol/L)	6847 ± 1044	4998 ± 331***

Data are the mean ± standard deviation. ***p<0.001, *p<0.05; compared with controls.

ORAC; oxygen radical absorbance capacity
M; male, F; female

Table 4 Fatty acid composition of phospholipids in plasma and neutrophils of controls and patients with Crohn's disease

	Plasma phospholipids		Neutrophil phospholipids	
	Controls (n=17)	Patients (n=20)	Controls (n=17)	Patients (n=20)
Saturated fatty acid	44.35 ± 6.25	51.63 ± 1.98***	60.83 ± 11.06	48.87 ± 5.21**
Polyunsaturated fatty acid	42.22 ± 6.42	32.19 ± 5.00***	18.51 ± 5.41	25.35 ± 4.29**
Total n-6 PUFA	32.49 ± 4.33	23.91 ± 0.12***	14.54 ± 5.88	20.90 ± 3.93**
Linoleic acid	21.11 ± 2.71	13.60 ± 5.16***	7.33 ± 4.57	7.47 ± 1.95
Arachidonic acid	8.32 ± 2.18	6.93 ± 1.02*	4.32 ± 2.99	9.23 ± 2.10*
Total n-3 PUFA	9.73 ± 3.37	8.28 ± 3.30	3.97 ± 2.58	4.46 ± 1.80
EPA	2.08 ± 1.12	1.91 ± 1.05	1.33 ± 0.99	0.90 ± 0.46
DHA	6.28 ± 2.42	5.37 ± 2.14	1.08 ± 0.70	1.95 ± 1.07*
Arachidonic acid/Linoleic acid	0.40 ± 0.11	0.59 ± 0.25**	0.69 ± 0.37	1.35 ± 0.59***

Data are the mean ± standard deviation. ***p<0.001, **p<0.01, *p<0.05; compared with controls.

PUFA; polyunsaturated fatty acid, EPA; eicosapentaenoic acid, DHA; docosahexaenoic acid

significantly lower in the patients. However, no significant difference was observed in the serum α -tocopherol level between the controls and the CD patients. Significant correlations between the serum ORAC value and zinc ($r=0.797$, $p<0.001$) concentrations were observed in the CD patients.

Discussion

In the CD patients studied, serum total protein and albumin levels were significantly lower than levels in controls, however, they remained within the normal range and there were no patients classified as malnourished. The CD patients were instructed to consume a diet rich in energy and protein, but restricted in fat and dietary fiber, and they followed their dietitian's advice well. Fifteen of 20 CD patients were nourished with an elemental diet, having high energy and containing high amino acid levels, a nitrogen source, vitamins and minerals and low in fat and dietary fiber.

Arachidonic acid is generally not abundant in natural foods and is mostly synthesized from linoleic acid by desaturation and chain elongation in the liver. Linoleic acid intake was lower in the CD patients than the controls, and as a result, linoleic acid and arachidonic acid molar percentages in the plasma phospholipids of the patients were reduced. Contrary to the plasma phospholipids, significant increases of the levels of n-6 PUFA and arachidonic acid in neutrophil phospholipids were observed in the CD patients. The patients were medicated with 5-ASA and/or azathioprin. 5-ASA provide anti-inflammatory and immuno-suppressing effects by inhibiting the synthesis of eicosanoid from arachidonic acid by the cyclooxygenase and lipoxygenase pathways [15, 16]. Therefore, inhibition of the metabolism of arachidonic acid may induce such an accumulation of arachidonic acid in neutrophil phospholipids and this may be followed by an increase in linoleic acid.

An increase in the arachidonic acid concentration of phospholipids may be accompanied by a rise in phospholipase A2 activity within the intestinal mucosa [17]. Leukotriene (LT) B4 is a prominent product of arachidonic acid metabolism in neutrophils, and a chemotactic factor that facilitates the accumulation of neutrophils with the consequent pro-

duction of reactive oxygen species causing damage from oxidative stress [18]. Eicosapentaenoic acid (EPA) competitively inhibits the cyclooxygenase and lipoxygenase pathways and reduces the production of LTB4 [19], which demonstrated a substantial reduction in clinical relapse rate among patients with CD in clinical [20]. An n-3 fatty acid-rich diet prevented an early response to elevated levels of interleukin (IL)-6 compared with an n-6 fatty acid-rich diet in trinitrobenzene sulfonic acid-induced enteritis [21]. A decrease in EPA and increase in arachidonic acid in neutrophils may not be beneficial for CD patients. Further restriction of dietary linoleic acid and supplementation of EPA may facilitate the continuance of remission in CD patients.

The present CD patients in this study had higher protein diets than the controls. Shoda et al. [5] suggested that a high meat diet rich in sulphur and sulphate may be implicated in relapses of CD. Amino acids containing sulphur are abundant in animal proteins but not in soy protein. Soy products such as soy-curd and soy-milk may be recommended as a source of protein for CD patients.

The role of relapse rate in patients with quiescent IBD treated with soluble dietary fiber, which is a substrate precursor for the production of butyrate in the colon, was not higher than that of patients given 5-ASA at the usual maintenance dose [22]. Although the intake of dietary fiber, both soluble and insoluble, in the studied CD patients was the same as that in the controls, the total fiber intake was less than that considered adequate for Japanese adults [23]. A therapeutic approach using dietary fiber, especially soluble fibers acting as prebiotics, may also be possible in CD.

Retinol and β -carotene are fat-soluble vitamins; therefore, the low fat diets may be an explanation for the low serum levels of fat-soluble vitamins observed in the present CD patients.

The significant decrease in the serum ORAC value and significant correlations between the serum ORAC value and serum zinc levels observed in the present patients may indicate a deficiency of antioxidative trace minerals. Reactive oxygen metabolites such as superoxide and hydroxyl radicals are produced by activated neutrophils and macrophages and are considered to contribute to the tissue damage seen in IBD. Increases in the concentrations of reac-

tive oxygen species have been found in the plasma and mucosa of patients with CD [24]. Supplementation of antioxidant trace minerals and vitamins may be beneficial for CD patients.

From the present observations, diets restricting the intake of vegetable oils rich in linoleic acid and providing EPA from fish and antioxidative trace minerals and vitamins may be recommended for the nutritional management of CD patients. These recommendations, however, should be tested in further examinations.

References

1. Geerling BJ, Stockbrugger RW and Brummer R-JM: Nutrition and inflammatory bowel disease: an update. *Scand J Gastroenterol* (1999) **230**: 95-105.
2. Gassull MA: Nutrition and inflammatory bowel disease: its relation to pathophysiology, outcome and therapy. *Dig Dis* (2003) **21**: 220-227.
3. Sakamoto N, Kono S, Wakai K, Fukuda Y, Satomi M, Shimoyama T, Inaba Y, Miyake Y, Sasaki S, Okamoto K, Kobashi G, Washio M, Yokoyama T, Date C, Tanaka H and The Epidemiology Group of the Research Committee on Inflammatory Bowel Disease in Japan: Dietary risk factors for inflammatory bowel disease: a multicenter case-control study in Japan. *Inflamm Bowel Dis* (2005) **11**: 154-163.
4. Shinil S: Dietary afactors in the Modulation of Inflammatory Bowel Disease Activity. *Medscape General Medicine*. 2007; **9** (1): 60
5. Shoda R, Matueda K, Yamato S, and Umeda N: Epidemiologic analysis of Crohn disease in Japan: increased dietary intake of n-6 polyunsaturated fatty acids and animal protein relates to the increased incidence of Crohn disease in Japan. *Am J Clin Nutr*. 1996; **63**: 741-745.
6. Cashman KD and Shanahan F: Is nutrition an aetiological Factor for inflammatory bowel disease? *Eur J Gastroenterol Hepatol*. 2003; **15**: 607-613.
7. Calder PC: n-3 Fatty acids, inflammation, and immunity-Relevance to postsurgical and critically ill patients. *Lipids* (2004) **39**: 1147-1161.
8. D'Odorico A, Bortolan S, Cardin R, D'Inca' R, Martines D, Ferronato A and Sturniolo GC: Reduced plasma antioxidant concentrations and increased oxidative DNA damage in inflammatory bowel disease. *Scand J Gastroenterol* (2001) **36**: 1289-1294.
9. Schachter H, Kirsner JB: Definitions of inflammatory bowel disease of unknown etiology. *Gastroenterology* (1975) **68**: 591-600.
10. Suzuki K, Sasagawa T, Okita M, Fujiwara Y, Mori K, Saito M and Abe Y: Development of new simplified-food frequency method for use in the surveillance on lifestyle in order to promote healthy condition in Okayama Prefecture, computed by Microsoft Excel. *Bull Facul Health Welfare Sci Okayama Prefec. Univ* (1996) **3**: 143-153.
11. Bligh EG and Dyer WJ: A rapid method of total lipid extraction and purification. *Can. J. Biochem. Physiol* (1959) **37**: 911-917.
12. Okita M, Tomioka K, Ota Y, Sasagawa T, Osawa T, Sakai N, Kawaguchi M and Itoshima T: Arachidonic acid in mononuclear cells and its clinical significance in HCV cirrhotic patients. *Nutrition* (2003) **19**: 727-732.
13. Milne DB and Botnen J: Retinol, α -tocopherol, lycopene, and α - and β -carotene simultaneously determined in plasma by isocratic liquid chromatography. *Clin Chem* (1986) **32**: 874-876.
14. Cao G and Prior RL: Measurement of oxygen radical absorbance capacity in biological samples. *Method in Enzymology* (1999) **299**: 50-62.
15. Hawkey CJ, Boughton-Smith NK and Whittle BJ: Modulation of human colonic arachidonic acid metabolism by sulfasalazine. *Dig Dis Sci* (1985) **30**: 1161-1165.
16. Peskar BM, Dreyling KW, May B, Schaarschmidt K and Goebell H: Possible mode of action of 5-aminosalicylic acid. *Dig Dis Sci* (1987) **32** (Suppl): 51S-56S.
17. Minami T, Tojo H, Shinomura Y, Matsuzawa Y and Okamoto M: Increased group II phospholipase A2 in colonic mucosa of patients with Crohn's disease and ulcerative colitis. *Gut* (1994) **35**: 1593-1598.
18. Samuelsson B: Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. *Science* (1983) **220**: 568-575.
19. James MJ, Gibson RA and Cleland LG: Dietary polyunsaturated fatty acids and inflammatory mediator production. *Am. J. Clin. Nutr* (2000) **71** (suppl): 343S-348S.
20. Belluzzi A, Brignola C, Campieri M, Pera A, Boschi S and Migliolo M: Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. *N Engl J Med* 1996; **334**: 1557-1560.
21. Andoh A, Tsujikawa T, Ishizuka I, Araki Y, Sasaki M, Koyama S and Fujiyama Y: N-3 fatty acid-rich diet prevents early response of interleukin-6 elevation in trinitrobenzene sulfonic acid-induced enteritis. *Int. J. Mol. Med* (2003) **12**: 721-725.
22. Galvez J, Rodrigues-Cabezas ME and Zarzuelo A: Effects of dietary fibre on inflammatory bowel disease. *Mol. Food Res.* (2005); **49**, 601-608
23. Oku T: Dietary reference intake for Japanese (2005): Carbohydrate and dietary fiber. *Rinshou Eiyou (Jap J Clin Nutr, Tokyo)* (2004) **105**: 837-839.
24. Keshavarzian A, Sedghi S, Kanofsky J, List T, Robinson C, Ibraham C and Winship D: Excessive production of reactive oxygen metabolites by inflamed colon: analysis by chemiluminescence probe. *Gastroenterology* (1992) **103**: 177-185.

Accepted March 30, 2007.